index - Myasthenia Gravis: étiologie, physiopathologie & approches thérapeutiques

Dernières publications

Chiffres clés

58 Publications avec texte intégral

Open Access

47 %

Mots clés

Germinal centers Autoimmune disease Complete Freund's adjuvant CXCL13-CXCR5 Myasthénie grave Experimental models Centres germinatifs ectopiques Age Inflammatory cytokines Antimir-150 Chemokines Heart failure B cells Chronic inflammation Thymoma Human myoblasts Thymic epithelial cells Experimental mouse models DICER M3243AG Interleukin 23 Immunotherapy Thymectomy Interferon de type I FMR1 Germinal center Interféron de type I Myasthenia Gravis MG Early-onset myasthenia gravis Acetylcholine receptor antibodies PBMC Lamin A/C nuclei Genetics Neuromuscular junction Innate immunity Immune response Myoblasts Transcriptome Myasthenia Gravis Auto-immunité Ferrites Thymus Il-23 CTCF Chemokine Gd T cells Cytokines Interleukine-23 CCL21 Cellules th17 Animal models Acides nucléiques endogènes Ectopic germinal centers Inflammation Autoimmunity AChR antibodies Adaptive immunity Etiology BAFF Interferon-β Aldehyde dehydrogenase biological marker CD31 antigen CD34 antigen CD45 antigen CD56 antigen adipocyte animal experiment animal model animal tissue antigen expression article cell differentiation cell function cell isolation cell labeling cell population cell selection controlled study endomysium enrichment culture enzyme activity enzyme substrate flow cytometry human human cell human tissue immunofluorescence in vitro study in vivo study mouse muscle biopsy muscle contraction muscle injury nonhuman phenotype skeletal muscle stem cell transplantation Adipogenesis Aldehyde Dehydrogenase Cell Differentiation Cells Cultured Flow Cytometry Humans Immunohistochemistry Muscle Cells Muscle Development Muscle Skeletal Phenotype MG patients MND Fragile X syndromes Immune regulation Gender Th17 cells Immunity Autoimmunity Inflammation Neuromuscular junction Germinal centers Th17 Muscle regeneration Anticorps monoclonal Follicular hyperplasia Experimental autoimmune myasthenia gravis Interferon type-I Quality of life Interferon Disease susceptibility COVID-19 Myasthenia gravis Assay comparison Acetylcholine receptors Endogenous nucleic acids Glucocorticoids LMNA CD31 Conduction disease Cardiomyopathy Interferon IFN Immunology and Microbiology Section Clinical cell transplantation Chronicity Interferon type I Autoimmune diseases Acetylcholine receptor Long-term follow-up Exercise Genetic associations COX2 Experimental autoimmune myasthenia gravis EAMG Cell-cell communication Interferonopathy